In a placebo controlled Phase 2 study of birinapant co-administered with azacitidine in first line higher risk patients suffering from myelodysplastic syndromes (MDS), birinapant did not demonstrate any clinical benefit over placebo on the primary endpoint of response rate after four months of therapy and met the bounds for futility. This interim analysis included the first 62 patients randomized in the trial. This study will now be terminated.
在birinapant安慰剂对照2期研究共同给予用氮杂胞苷在第一行较高风险的患者从骨髓增生异常综合征(MDS)的痛苦,birinapant并四个月的治疗后没有表现出优于安慰剂任何临床受益上的响应速度的主要终点满足了界限徒劳。这个中期分析包括第62例患者随机分为试验。这项研究现在将终止。作者: jogger2015 时间: 2016-1-8 16:04
1. Birinapant MDS Ph2b interim data 预计明年1月初; 2. SHAPE CTCL Program Ph2 data 明年1月初;;3. Birinapant/KEYTRUDA(R) Program Ph1预计年底启动, 默克合作项目;4. Birinapant HBV Program 明年上半年在印度重新开展实验;